Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. (September 2017)

• Record Type: Journal Article
• Authors: Le Burel, Sébastien; Champiat, Stéphane; Mateus, Christine; Marabelle, Aurélien; Michot, Jean-Marie; Robert, Caroline; Belkhir, Rakiba; Soria, Jean-Charles; Laghouati, Salim; Voisin, Anne-Laure; Fain, Olivier; Mékinian, Arsène; Coutte, Laetitia; Szwebel, Tali-Anne; Dunogeant, Laetitia; Lioger, Bertrand; Luxembourger, Cécile; Mariette, Xavier; Lambotte, Olivier
• Is Part Of: European journal of cancer. Volume 82(2017)
• Page Start: 34
• Page End: 44
• Publication Date: 2017-09
• Subjects: Immunotherapy -- Connective tissue diseases -- Rheumatic diseases -- Immune thrombocytopenia; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2017.05.032
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Aim: The growing use of immune checkpoint inhibitors (ICIs) is associated with the occurrence of immune-related adverse events (irAEs). Few data are published on systemic, immunohaematological and rheumatic irAEs. In a pharmacovigilance database analysis, we screened for these irAEs and calculated their prevalence. Patients and methods: Participants were recruited via Registre des Effets Indésirables Sévères des Anticorps Monoclonaux Immunomodulateurs en Cancérologie (REISAMIC) 1 a French registry of grade ≥2 irAEs occurring in ICI-treated patients. The pathologies of interest were systemic autoimmune and inflammatory diseases, rheumatic diseases and immune cytopenia. Results: Out of 908 patients treated with anti-Programmed cell Death 1 (PD1)/anti-Programmed cell Death-Ligand 1 (PD-L1) agents (together with an anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) agent in 40 cases) between December 2012 and December 2016 at a single centre, 21 patients experienced systemic irAEs. The types and the prevalence of irAEs were as follows: immune thrombocytopenia (0.2%), Sjögren syndrome (0.3%), rheumatoid arthritis (0.2%), polymyalgia rheumatica (0.2%), psoriatic arthritis (0.2%), seronegative polyarthritis (0.7%) and sarcoidosis (0.2%). Patients with Sjögren syndrome or seronegative polyarthritis were more likely to have received combination therapy with ipilimumab (2.5% for both). We described these 21 cases, together with nine additional cases from five other centres. Most irAE were moderately severe (grade 2, 63%). The median time to onset was 57°days (interquartile range (IQR) 24–117). The ICI was withdrawn in 12 cases, 25 patients (83%) received corticosteroids, and five patients (17%) received immunosuppressant/immunomodulatory agents. The irAEs resolved fully or partially in 28 cases (93%). Conclusion: Although systemic, immunohaematological and rheumatic diseases are rarely associated with ICI use, the prevalence is higher when two ICIs are combined. Corticosteroids are often effective and may enable the continued administration of ICIs. Studies designed to identify at-risk patients are warranted. Highlights: The prevalence of systemic immune-related adverse events (irAEs) associated with anti-Programmed Cell Death-1 (PD1)/anti-Programmed Cell Death Ligand-1 (PD-L1) use is low but increases with combination therapy. Oncologists have to be able to recognise systemic irAEs associated with anti-PD1/anti-PD-L1 agents. Systemic irAEs usually respond well to treatment with corticosteroids. Biological profiling might help to identify patients at risk of developing systemic irAEs.